Replimune Group, Inc. (NASDAQ:REPL) Director Fund Iv L.P. Omega sold 5,537 shares of the business’s stock in a transaction on Thursday, September 16th. The stock was sold at an average price of $32.55, for a total transaction of $180,229.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NASDAQ REPL traded down $1.07 during trading on Monday, hitting $31.51. 5,967 shares of the company traded hands, compared to its average volume of 339,206. The company has a debt-to-equity ratio of 0.05, a quick ratio of 30.87 and a current ratio of 30.87. Replimune Group, Inc. has a fifty-two week low of $20.40 and a fifty-two week high of $54.85. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -17.71 and a beta of 2.48. The business’s fifty day moving average is $32.21 and its 200 day moving average is $33.49.
Replimune Group (NASDAQ:REPL) last posted its earnings results on Friday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.09). On average, analysts predict that Replimune Group, Inc. will post -2.18 EPS for the current year.
Several analysts recently weighed in on the stock. SVB Leerink reduced their price objective on shares of Replimune Group from $55.00 to $49.00 and set an “outperform” rating on the stock in a research note on Monday, August 23rd. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Replimune Group in a research note on Monday, August 9th. Finally, Zacks Investment Research cut shares of Replimune Group from a “hold” rating to a “sell” rating in a research note on Thursday, August 12th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $55.13.
About Replimune Group
Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.
Read More: What is the Fibonacci sequence?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.